Search →

Press Releases

Date
Title
Date
02/14/23
Title
Bicycle Therapeutics Announces Phase I Dose Escalation Results from Ongoing Phase I/II Study of BT8009
Date
02/08/23
Title
Bicycle Therapeutics to Participate in the SVB Securities Global Biopharma Conference
Date
01/11/23
Title
Bicycle Therapeutics to Present End of Dose Escalation Data from Ongoing Phase I/II Study of BT8009 at the 2023 ASCO Genitourinary (GU) Cancers Symposium
Date
01/04/23
Title
Bicycle Therapeutics Announces FDA Fast Track Designation Granted to BT8009 for the Treatment of Adult Patients with Previously Treated Locally Advanced or Metastatic Urothelial Cancer
Overview →Stock Information →SEC Filings →UK Annual Reports →Governance + Leadership →Presentation + Events →Analyst Coverage →Press Releases →Investor Resources →

Search